Peptide record

TPDB77632

[Ala7-C-αGal(Ac)4]de [Ala7-C-αGal]dermorp [Ser7-O-βGlc(Ac)4]de [Ser7-O-βGlc]dermorp Dermorphin Blood-Brain Barrier modified_plain modified

11 amino acids

TPDB ID TPDB77632

Peptide_Name

[Ala7-C-αGal(Ac)4]de [Ala7-C-αGal]dermorp [Ser7-O-βGlc(Ac)4]de [Ser7-O-βGlc]dermorp Dermorphin

Activity

Blood-Brain Barrier

Activity_category_statistics

Delivery and barrier-penetrating peptides

Database_Source

Peptipedia

Sequence_Type

modified_plain

Has_Modification Yes

Description A 11-aa modified blood-brain barrier peptide sequence curated from Peptipedia, without an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

YaFGYPS-NH2

FASTA

>TPDB77632|Blood-Brain Barrier|length=11
YaFGYPS-NH2

Formula C50H62N12O14

Absent Amino Acids RDCEQILKMTWV

Common Amino Acids Y

Mass 1055.11

PI 7.71

Basic Residues 1

Acidic Residues 0

Hydrophobic Residues 4

Net Charge +0

Boman Index -1.21

Hydrophobicity -0.682

Aliphatic Index 9.09

Half Life

Mammalian: 2.8 hour Yeast: 10 min E.coli: 2 min

Extinction Coefficient Cystines 2980

Absorbance 280nm 282.43

Polar Residues 4

number

Amino Acid Distribution

A: 1 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 1 I: 0 L: 0 K: 0 M: 0 F: 1 P: 1 S: 1 T: 0 W: 0 Y: 2 V: 0

Length

Formula

C50H62N12O14

Mass

1055.11

7.71

Net Charge

Boman Index

-1.21

Hydrophobicity

-0.682

Conformation

Linear

Peptide_Length

Similarity

Peptide_Sequence_3Letter

Tyr-(D)Ala-Phe-Gly-Tyr-Pro-Ser-NH2

SMILES

O=C(NC(C(=O)N)CO)C4N(C(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccc(O)cc1)C)Cc2ccccc2)Cc3ccc(O)cc3)CCC4

Evidence 1 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 10.29%

Assay & Model

In Vitro Method Capillary depletion

Animal Model Origin/Source

Response % capillary

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin Chemically synthesized

Label Direct iodination

Evidence 2 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 89.71%

Assay & Model

In Vitro Method Capillary depletion

Animal Model Origin/Source

Response % parenchyma

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin Chemically synthesized

Label Direct iodination

Evidence 3 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 0.0000114

Assay & Model

In Vitro Method Antinociception

Animal Model Origin/Source

Response ICV/SC ratio

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin Chemically synthesized

Transport Type Permeability

Evidence 4 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 0.00218 mL/(g x min)

Assay & Model

Animal Model Origin/Source

Response Unidirectional influx rate constant

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin Chemically synthesized

In Vivo Mode of Delivery Intravenous

Transport Type Saturable

Label Direct iodination

Evidence 5 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 0.02148 ml/g

Assay & Model

Animal Model Origin/Source

Response Initial disrobution volume

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin Chemically synthesized

In Vivo Mode of Delivery Intravenous

Transport Type Saturable

Label Direct iodination

Evidence 6 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 0.01398 ml/g

Assay & Model

Animal Model Origin/Source

Response Initial disrobution volume

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin Chemically synthesized

In Vivo Mode of Delivery Intravenous

Transport Type Permeability

Label Direct iodination

Evidence 7 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 0.00063 mL/(g x min)

Assay & Model

Animal Model Origin/Source

Response Unidirectional influx rate constant

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin Chemically synthesized

In Vivo Mode of Delivery Intravenous

Transport Type Permeability

Label Direct iodination

Evidence 8 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 0.00019 mL/(g x min)

Assay & Model

Animal Model Origin/Source

Response Unidirectional influx rate constant

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin Chemically synthesized

In Vivo Mode of Delivery Intravenous

Transport Type Permeability

Label Direct iodination

Evidence 9 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 0.00035 mL/(g x min)

Assay & Model

Animal Model Origin/Source

Response Unidirectional influx rate constant

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin Chemically synthesized

In Vivo Mode of Delivery Intravenous

Transport Type Permeability

Label Direct iodination

Evidence 10 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 0.0000195

Assay & Model

In Vitro Method anti-nociception

Animal Model Origin/Source

Response ICV/SC ratio

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin human

Transport Type Permeability

Evidence 11 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 0.0000098

Assay & Model

In Vitro Method anti-nociception

Animal Model Origin/Source

Response ICV/SC ratio

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin human

Transport Type Permeability

Evidence 12 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 0.0000334

Assay & Model

In Vitro Method anti-nociception

Animal Model Origin/Source

Response ICV/SC ratio

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin Chemically synthesized

Transport Type Permeability

Evidence 13 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 0.0000089

Assay & Model

In Vitro Method anti-nociception

Animal Model Origin/Source

Response ICV/SC ratio

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin Chemically synthesized

Transport Type Permeability

In_Vivo_Mode_of_Delivery

Intravenous